Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05868395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 24, 2023 to Jan 2, 2024 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date changed from estimate of May 24, 2023 to Jan 2, 2024
    • Study sites: 0 to 1
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma
Trial Details
NCT Number NCT05868395
Lead Sponsor Medical University of Vienna
Conditions Mantle-cell Lymphoma
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov